Barinthus Biotherapeutics plc.
barinthusbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2026 10-Q, filed Aug 6, 2026. Its latest SEC filing is a 15-12G from Sep 21, 2026.
10-Q for Q2 FY2026, filed Aug 6, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops drug candidates designed to guide immune responses for people with autoimmune and inflammatory diseases, including celiac disease.
10-K for FY2025, filed Mar 13, 2026We are a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and…View ↗
We are prioritizing the development of a pipeline for I&I indications enabled by our proprietary and highly differentiated platform for…View ↗
We aim to directly address the disease process underlying autoimmunity and other inflammatory diseases by developing antigen-specific…View ↗
Who Were Their Customers?
Collaboration partners can obtain licenses or options to license product candidates; Barinthus also seeks partners to take forward some of its legacy candidates.
10-K for FY2025, filed Mar 13, 2026
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$10.6MView ↗
- ▼ −50% (Loss)
- vs −$21.1M in Q2 FY2025
-
Sep 9, 2026
Topco acquired Barinthus in the Clywedog transaction
Former shareholders exchanged their Barinthus shares for Topco stock, and Barinthus ADSs ceased public trading.
Sources
8-K, filed Sep 9, 2026
Pursuant to the Merger Agreement and the Scheme of Arrangement, at the Scheme Effective Time, Topco acquired all of the issued and to be…View ↗
A narrower disease focus
The older report described treatments and preventive vaccines across infectious diseases, cancer, and autoimmunity; the latest prioritizes immune-tolerance treatments for autoimmune and inflammatory diseases, with infectious disease and oncology candidates to advance only through partners.
10-K for FY2022, filed Mar 24, 2023 10-K for FY2025, filed Mar 13, 2026We are prioritizing the development of a pipeline for I&I indications enabled by our proprietary and highly differentiated platform for…View ↗
In January 2025, we announced a strategic business refocus and restructuring to prioritize immunology and inflammation indications…View ↗
In January 2025, we announced a strategic focus on developing a pipeline in I&I, and the deprioritization of our programs in infectious…View ↗
Loading...
